Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Katerina Fountoulaki , Nikolaos Dagres , Efstathios K Iliodromitis Added: 3 years ago
Heart failure (HF) is a feared endpoint for most cardiovascular diseases and is a major cause of morbidity and mortality. The worldwide prevalence of HF is between 2 and 3 % and rises sharply at around 75 years of age, so that the prevalence in 70- to 80-year-old people is between 10–20 %. With a 50 % 5-year survival rate, HF is predicted to be the leading cause of all morbidity by 2020.1,2… View more
Author(s): Edoardo Bertero , Pietro Ameri , Christoph Maack Added: 3 years ago
Heart failure (HF) and cancer represent two major causes of morbidity and mortality in developed countries.1,2 The prevalence of these conditions is growing as the age of the population and the burden of shared risk factors, such as diabetes and obesity, are constantly increasing. In past decades, the field of cardio-oncology has predominantly focused on prevention and treatment of cardiovascular… View more
Author(s): Alessandra Cuomo , Alessio Rodolico , Amalia Galdieri , et al Added: 3 years ago
The increasing progress in cancer therapies has reduced mortality rates for many cancers. Unfortunately, many life-saving therapies are burdened by the risk of cardiotoxicity (CTX). The cardiovascular system appears to be particularly susceptible to the action of many anti-neoplastic drugs, which may cause vasospastic or thromboembolic ischaemia, arterial hypertension, dysrhythmia, and left… View more
Author(s): Carine E Hamo , Michelle W Bloom Added: 3 years ago
Heart disease and cancer are the two leading causes of death, together accounting for almost 50 % of deaths in the US.1 Unfortunately, the tremendous success in improving cancer survival is often attenuated by downstream cardiovascular complications from cancer therapy. Acute cardiac toxicity may limit the ability to use life-saving cancer therapy and chronic toxicity limits overall survival. As… View more